Increased persistent sodium current due to decreased PI3K signaling contributes to QT prolongation in the diabetic

Zhongju Lu1, Ya-Ping Jiang, Chia-Yen C Wu

  • 1Department of Physiology and Biophysics and the Institute for Molecular Cardiology, Stony Brook University, Stony Brook, New York.

Diabetes
|August 27, 2013
PubMed

Insights

Diabetes increases the risk of sudden cardiac death by prolonging the QT interval due to reduced phosphoinositide 3-kinase (PI3K) signaling, which elevates the persistent sodium current (INaP). This mechanism explains increased arrhythmias in diabetic patients.

Area of Science:

  • Cardiology
  • Diabetology
  • Molecular Biology

Background:

  • Diabetes is a significant risk factor for sudden cardiac death and arrhythmias.
  • QT interval prolongation, a marker for arrhythmias, is more prevalent in diabetic patients.
  • The underlying mechanisms linking diabetes to QT prolongation are not well understood.

Purpose of the Study:

  • To investigate the role of phosphoinositide 3-kinase (PI3K) signaling in diabetes-induced QT interval prolongation.
  • To elucidate the specific ion channel alterations contributing to this complication.

Main Methods:

  • Studied cardiac myocytes from type 1 and type 2 diabetic mouse models.
  • Manipulated PI3K signaling pathways and measured action potential duration (APD) and ion currents.
  • Administered insulin, PI3K inhibitors, and INaP blockers to assess their effects on QT interval.

Main Results:

  • Diabetic myocytes showed increased APD and persistent sodium current (INaP), which were normalized by PI3K activation.
  • QT interval prolongation in diabetic mice was reversed by PI3K activation or INaP blockade.
  • Insulin treatment shortened the QT interval in type 1 diabetic hearts, an effect blocked by a PI3K inhibitor.

Conclusions:

  • Downregulation of cardiac PI3K signaling in diabetes leads to QT interval prolongation, partly via increased INaP.
  • This PI3K-INaP pathway is a key mechanism underlying increased arrhythmia risk in diabetic patients.
  • Targeting PI3K signaling or INaP may offer therapeutic strategies for diabetic cardiovascular complications.

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.